Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Colorectal Neoplasms 135Neoplasms 37Pancreatic Neoplasms 34Stomach Neoplasms 27Colonic Neoplasms 23Neoplasm Metastasis 20Rectal Neoplasms 17Carcinoma, Non-Small-Cell Lung 15Esophageal Neoplasms 10Cholangiocarcinoma 10Adenocarcinoma 9Parkinson Disease 4, Autosomal Dominant Lewy Body 8Biliary Tract Neoplasms 8Adenocarcinoma Of Esophagus 8Ovarian Neoplasms 7Triple Negative Breast Neoplasms 6Gallbladder Neoplasms 6Esophageal Squamous Cell Carcinoma 6Gastrointestinal Neoplasms 5Digestive System Neoplasms 5Breast Neoplasms 5Advanced Solid Tumors 5Squamous Cell Carcinoma of Head and Neck 4Solid Tumors 4Melanoma 4Intestinal Neoplasms 4Carcinoma, Pancreatic Ductal 4Carcinoma, Hepatocellular 4Advanced Solid Tumor 4Small Cell Lung Carcinoma 3

Interventions

pembrolizumab 51Nivolumab 27Gemcitabine 23atezolizumab 19Cisplatin 18Carboplatin 18enfortumab vedotin 15avelumab 15Mitomycin 14Docetaxel 8Ipilimumab 7Paclitaxel 6Injections 5Cyclophosphamide 5vinflunine 4toripalimab 4tislelizumab 4lenvatinib 4fludarabine 4epacadostat 4Pemetrexed 4130-nm albumin-bound paclitaxel 4sacituzumab govitecan 3disitamab vedotin 3Rogaratinib 3Interleukin-2 3ALT-803 3vofatamab 2valrubicin 2rucaparib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Transitional Cell × Leucovorin × Clear all
NCT03197571 2025-02-21

QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

ImmunityBio, Inc.

Phase 1/2 Withdrawn
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡